CURE.AU GLOBAL X S&P BIOTECH ETF
Market Closed 05-17 16:12:00 AEST
47.19
-0.15
-0.32%
High
47.50
Low
47.19
Vol
606.00
Open
47.50
D1 Closing
47.34
Amplitude
0.65%
Mkt Cap
0.00
Tradable Cap
39.83M
Total Shares
0.00
T/O
28.63K
T/O Rate
0.07%
Tradable Shares
844.01K
P/B
--
ROE
--
EPS
0.00
52wk High
--
52wk Low
--
P/E
--
Dividend
--
Div.Yield
--
ROA
--
Time
5D
D
W
M
News
New Post(s)
Profile
The return of the operating leverage
LiveWire · 05-09
The return of the operating leverage
Investing in Pharma: The drug lifecycle
LiveWire · 04-24
Investing in Pharma: The drug lifecycle
10 adviser-approved ETFs for 2024
LiveWire · 03-25
10 adviser-approved ETFs for 2024
Why ETF watchlists can help you become a better investor
LiveWire · 03-18
Why ETF watchlists can help you become a better investor
How to build a portfolio of ETFs
LiveWire · 2023-12-12
How to build a portfolio of ETFs
No data available
Introduction
Company Name.
GLOBAL X S&P BIOTECH ETF
Affiliated Markets:
ASX
Listing Date:
--
Main Business:
Issue price:
--
{"stockData":{"symbol":"CURE.AU","market":"AU","secType":"STK","nameCN":"GLOBAL X S&P BIOTECH ETF","latestPrice":47.19,"timestamp":1715926320000,"preClose":47.34,"halted":0,"volume":606,"delay":0,"nameEN":"GLOBAL X S&P BIOTECH ETF","floatShares":844012,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-0.15,"latestTime":"05-17 16:12:00 AEST","open":47.5,"high":47.5,"low":47.19,"amount":28632,"amplitude":0.006548,"askPrice":48,"askSize":20,"bidPrice":46.75,"bidSize":25,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1716163200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":47.34,"sharesOutstanding":844012,"nav":47.19,"aum":39971529,"bidAskSpread":0,"openAndCloseTimeList":[[1715904000000,1715925600000]],"volumeRatio":0.4923626749313397,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/CURE.AU/tweets","defaultTab":"tweets","newsList":[{"id":"2434083008","title":"The return of the operating leverage","url":"https://stock-news.laohu8.com/highlight/detail?id=2434083008","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2434083008?lang=en_us&edition=fundamental","pubTime":"2024-05-09 07:31","pubTimestamp":1715211106,"startTime":"0","endTime":"0","summary":"The return of operating leverage may be one of the most important but underappreciated developments in 2024 and could be quietly driving a positive shift in market sentiment. Operating leverage broadly refers to a company’s ability to translate sales into earnings. Historically, U.S. large cap companies grow earnings at 2–3 times sales. Starting in mid-2022 though, S&P 500 earnings grew slower than sales for six consecutive quarters. That trend reversed in Q4 2023 when the S&P 500 grew earnings by 8% year-over-year on sales of 4%. As we kick off the Q1 2024 earnings season, S&P 500 companies are expected to grow sales by 6.5% with EPS growth of 11.2% on margins of 12.8%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-return-of-the-operating-leverage","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-return-of-the-operating-leverage","is_publish_highlight":false,"gpt_icon":0},{"id":"2429245461","title":"Investing in Pharma: The drug lifecycle","url":"https://stock-news.laohu8.com/highlight/detail?id=2429245461","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2429245461?lang=en_us&edition=fundamental","pubTime":"2024-04-24 07:40","pubTimestamp":1713915623,"startTime":"0","endTime":"0","summary":"Drug development pipelines are the lifeblood of the pharmaceutical industry. It is crucial for investors to understand milestones like FDA approvals and the impact of losing exclusivity on profits to navigate the dynamic healthcare sector. This piece provides an investment-focused overview of a typical drug’s lifecycle.The regulatory process for investigational drugs is long and costly, but the rewards for successfully bringing a new drug to market can be vast.There are numerous potential pathways to accelerate the drug discovery process, which may notably impact a new drug’s return on investment.Generic competition can quickly eat into sales and reduce profit margins, leading investors to keep a close eye on new drug development.Allows clinical trials to utilise “surrogate endpoints” for clinical trials. Surrogate endpoints are markers or measurements that are considered reasonably likely to predict a real clinical benefit. These are common in cancer clinical trials, for example, wher","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/investing-in-pharma-the-drug-lifecycle","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/investing-in-pharma-the-drug-lifecycle","is_publish_highlight":false,"gpt_icon":0},{"id":"2422530975","title":"10 adviser-approved ETFs for 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2422530975","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2422530975?lang=en_us&edition=fundamental","pubTime":"2024-03-25 04:30","pubTimestamp":1711312216,"startTime":"0","endTime":"0","summary":"By now, you’re probably aware of the stats highlighting the growth of ETFs in Australia .But just because something is popular, doesn’t always mean it is good, or that people know how to use it effectively .So, for this latest episode of Buy Hold Sell, we reached out to two advisers - people actually using these products in client portfolios – to get their take on the good, the bad, and the ugly across various factors and investment styles.Be warned: When long-time friends Adam Dawes from Shaw and Partners and Andrew Wielandt from DP Wealth Advisory are together in the same room, there are often a few laughs to be had.But you will also get practical and sound guidance, free from any spin – these two call it how they see it. So make sure to watch the video to find out Adam and Andrew's top ETFs for growth, income, value, and quality - as well as the thematic ETFs they actually like right now.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/10-adviser-approved-etfs-for-2024","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/10-adviser-approved-etfs-for-2024","is_publish_highlight":false,"gpt_icon":0},{"id":"2420415243","title":"Why ETF watchlists can help you become a better investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2420415243","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2420415243?lang=en_us&edition=fundamental","pubTime":"2024-03-18 14:20","pubTimestamp":1710742844,"startTime":"0","endTime":"0","summary":"ETFs offer a convenient and cost-effective way to gain exposure to a diversified portfolio of assets but few investors will use them as a tool to track the performance of various sub-sectors and industries.When I first started investing – I loved to check the overnight performance of the S&P 500, Dow and Nasdaq. If they were green, I knew my portfolio was going to have a good day. But more often than not, the S&P 500 rips higher while the ASX 200 is doing absolutely nothing. This is where an ETF watchlist can help.Our Morning Wrap features a curated list of US-listed ETFs, offering deeper insights into overnight sector performance and what to expect in the upcoming session. The watchlist has a focus on sub-sectors from resources, healthcare, industrials and tech.Here’s what the ETF watchlist looked like on Monday, 18 March .A strong session for copper minesandSandfire opened the session 1.9% higher. The price action for the VanEck Gold Miners ETF was rather helpful","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/why-etf-watchlists-can-help-you-become-a-better-investor","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/why-etf-watchlists-can-help-you-become-a-better-investor","is_publish_highlight":false,"gpt_icon":0},{"id":"2390953273","title":"How to build a portfolio of ETFs","url":"https://stock-news.laohu8.com/highlight/detail?id=2390953273","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2390953273?lang=en_us&edition=fundamental","pubTime":"2023-12-12 07:43","pubTimestamp":1702338204,"startTime":"0","endTime":"0","summary":"Exchange-traded funds are a simple solution for investors just getting started or for those looking to expose their portfolio to a different part of the market. But how can you construct a portfolio of ETFs that showcase Core and Thematic strategies?Core ETFstypically refer to a group of exchange-traded funds that help form the foundation of a portfolio. These ETFs are designed to provide exposures to a market, asset class, or sector in which the investor holds a high conviction. In general, core ETFs are characterised by their low costs, diversified holdings, and long-term investment horizons.Thematic ETFscapitalise on the worlds constantly evolving landscape, and as it evolves, megatrends emerge. Megatrends are shifts in society that usually come in the form of significant advances in technology, or global dynamics which have the potential to reshape entire industries. As investors, these global macro-movements create long-lasting opportunities called ‘thematics’.Bonds, whether gove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/how-to-build-a-portfolio-of-etfs","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/how-to-build-a-portfolio-of-etfs","is_publish_highlight":false,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0292},{"period":"1month","weight":0.0346},{"period":"3month","weight":-0.0393},{"period":"6month","weight":0.2682},{"period":"1year","weight":0.0747},{"period":"ytd","weight":0.0308}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.0587},{"period":"3month","weight":0.0966},{"period":"6month","weight":0.1366},{"period":"1year","weight":0.1436},{"period":"ytd","weight":0.1212}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.020274},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.044983},{"month":3,"riseRate":0.5,"avgChangeRate":0.003888},{"month":4,"riseRate":0.5,"avgChangeRate":-0.00477},{"month":5,"riseRate":0.6,"avgChangeRate":0.026052},{"month":6,"riseRate":0.4,"avgChangeRate":-0.001239},{"month":7,"riseRate":0.4,"avgChangeRate":0.006163},{"month":8,"riseRate":0.2,"avgChangeRate":-0.023557},{"month":9,"riseRate":0.6,"avgChangeRate":-0.00265},{"month":10,"riseRate":0.6,"avgChangeRate":0.04941},{"month":11,"riseRate":0.5,"avgChangeRate":0.020215},{"month":12,"riseRate":0.833333,"avgChangeRate":0.004403}],"exchange":"ASX","name":"GLOBAL X S&P BIOTECH ETF","nameEN":"GLOBAL X S&P BIOTECH ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GLOBAL X S&P BIOTECH ETF(CURE.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GLOBAL X S&P BIOTECH ETF(CURE.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GLOBAL X S&P BIOTECH ETF,CURE.AU,GLOBAL X S&P BIOTECH ETF股票,GLOBAL X S&P BIOTECH ETF股票老虎,GLOBAL X S&P BIOTECH ETF股票老虎国际,GLOBAL X S&P BIOTECH ETF行情,GLOBAL X S&P BIOTECH ETF股票行情,GLOBAL X S&P BIOTECH ETF股价,GLOBAL X S&P BIOTECH ETF股市,GLOBAL X S&P BIOTECH ETF股票价格,GLOBAL X S&P BIOTECH ETF股票交易,GLOBAL X S&P BIOTECH ETF股票购买,GLOBAL X S&P BIOTECH ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GLOBAL X S&P BIOTECH ETF(CURE.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GLOBAL X S&P BIOTECH ETF(CURE.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}